- Home
- CNR vs DNLI Comparison
CNR vs DNLI Comparison
Compare CNR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNR | DNLI |
|---|---|---|
| Founded | 1864 | 2013 |
| Country | United States | United States |
| Employees | 4850 | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNR | DNLI |
|---|---|---|
| Price | $80.29 | $23.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $111.50 | $34.33 |
| AVG Volume (30 Days) | 483.6K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.26 | N/A |
| Revenue Next Year | $6.83 | $408.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $68.78 | $12.58 |
| 52 Week High | $114.80 | $27.30 |
Technical Indicators
Market Signals| Indicator | CNR | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 52.12 |
| Support Level | $75.76 | $18.07 |
| Resistance Level | $91.33 | $27.30 |
| Average True Range (ATR) | 2.74 | 1.15 |
| MACD | -0.19 | -0.09 |
| Stochastic Oscillator | 36.41 | 48.05 |
Price Performance
Historical ComparisonAbout CNR Core Natural Resources Inc.
Core Natural Resources Inc is a producer and exporter of metallurgical and thermal coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The activities of the company involves mining of thermal coal, power generation, and other related activities.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.